Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,045 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining efficacy and completion rates with no data imputation: a composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials.
Rabinowitz J, Werbeloff N, Caers I, Mandel FS, Jaeger J, Stauffer V, Menard F, Kinon BJ, Kapur S. Rabinowitz J, et al. Among authors: kapur s. Eur Neuropsychopharmacol. 2014 Mar;24(3):357-68. doi: 10.1016/j.euroneuro.2013.11.010. Epub 2013 Nov 28. Eur Neuropsychopharmacol. 2014. PMID: 24370073 Free article.
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.
Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, Kinon B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J. Marder SR, et al. Among authors: kapur s. Schizophr Res. 2013 Nov;150(2-3):328-33. doi: 10.1016/j.schres.2013.07.058. Epub 2013 Sep 9. Schizophr Res. 2013. PMID: 24028744 Review.
The promise of biological markers for treatment response in first-episode psychosis: a systematic review.
Fond G, d'Albis MA, Jamain S, Tamouza R, Arango C, Fleischhacker WW, Glenthøj B, Leweke M, Lewis S, McGuire P, Meyer-Lindenberg A, Sommer IE, Winter-van Rossum I, Kapur S, Kahn RS, Rujescu D, Leboyer M. Fond G, et al. Among authors: kapur s. Schizophr Bull. 2015 May;41(3):559-73. doi: 10.1093/schbul/sbv002. Epub 2015 Mar 10. Schizophr Bull. 2015. PMID: 25759473 Free PMC article. Review.
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.
Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, Glenthøj B, Leboyer M, Leweke FM, Lewis S, McGuire P, Meyer-Lindenberg A, Rujescu D, Kapur S, Kahn RS, Sommer IE. Leucht S, et al. Among authors: kapur s. Schizophr Bull. 2015 May;41(3):549-58. doi: 10.1093/schbul/sbv019. Epub 2015 Mar 18. Schizophr Bull. 2015. PMID: 25786408 Free PMC article. Review.
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S. Bugarski-Kirola D, et al. Among authors: kapur s. Lancet Psychiatry. 2016 Dec;3(12):1115-1128. doi: 10.1016/S2215-0366(16)30344-3. Epub 2016 Nov 2. Lancet Psychiatry. 2016. PMID: 27816567 Clinical Trial.
1,045 results